Abstract Chromosomal-scaffolding proteins exert DNA structural functions during mitosis, and gene regulatory functions such as RNA splicing/polymerization and DNA replication in interphase, allowing the progression of the cell cycle. Recently, it has been reported that topoisomerases play a key role in DNA repair, suggesting an additional regulatory mechanism of the chromosome structure on DNA metabolism and cell cycle checkpoints. Despite the progress made toward the understanding of the genome organization and expression, few changes have been reported in the chromosome scaffold of malignant cells associated with the cancer phenotype. In a previous work, we reported LFM-1 protein (Licensing Factor Model-1) as a chromosomal-scaffold component transiently associated with mitotic chromosomes in MDCK (Madin Darby canine kidney) epithelial cells (Vega-Salas and Salas 1996) . In this work, we explore LFM-1 expression in human epithelia with contrasting tumorigenicity during the progression of the cell cycle. Although cell metabolic labeling shows synthesis of a common 87-kDa LFM-1 precursor during G 2 -phase in both non-tumorigenic and cancer cells, surprisingly, the post-translational LFM-1 chromosomebound polypeptide displays a different apparent molecular weight and binding to chromosomes in the cancer phenotype. The finding of a highly phosphorylated LFM-1 60-kDa form with abnormal binding to chromosomes in human carcinoma cells suggests a structural/regulatory role(s) of the chromosome-scaffold/matrix in DNA metabolism in cancer-related events of cell proliferation.
Introduction
Chromosomal matrix or scaffold (Berezney and Coffey 1974; Paulson and Laemmli 1977; Earnshaw et al. 1985; Gasser et al. 1986 ) is the chromosome protein web that fastens to matrix/scaffold highly conserved repetitive DNA sequences named matrix regions (MARs) and scaffold regions (SARs) (Gasser et al. 1989 ; Von Kries et al. 1991; Saitoh et al. 1995; Wei et al. 1998) , and organizes the higher-order chromatin loops. It has been reported that this network is involved in the control of DNA functions such as chromosomal condensation, chromatid segregation (Mirkovich et al. 1984; Uemura et al. 1987; Wright and Shatten 1990; Saitoh et al. 1995; Subramanian et al. 1998) , and chromatin transcription and methylation (Hirano and Mitchison 1991; Stein et al. 1996) . Also, a regulatory role in DNA replication has been proposed, and it is reported that the specific binding of MAR/SAR proteins to DNA affects the nearby gene expression (Dijkwel et al. 1986; Gasser et al. 1989; Wright and Shatten 1990; Zlatanova and van Holde 1992; Hamlin 1992; Pernov et al. 1998) .
Cancer cells differ from the normal parental tissues in the fast, deregulated cell cycle progression. They seem to be partially or totally independent from extracellular signals (Durkin and Whitfield 1984; Guadagno and Assoian 1991; Takeichi 1993) and from intracellular regulatory cascades of phosphorylations (Kirchner 1992; Prevostel et al. 1998) , events that would control molecular changes and subcellular distribution of nuclear and cytoplasmic proteins involved in cell proliferation (Nasmyth et al. 1991; Getzember and Coffey 1991; Hatakeyama and Weinberg 1995; Getzember et al. 1996; de Belle et al. 1998; Saville and Watson 1998) . Over the last few years, mutated hyperphosphorylated nuclearmatrix proteins have been proposed to play a role in neoplastic processes (Kanuja et al. 1993; Keesee et al. 1994; Yang et al. 1997; Zeng et al. 1997) . However, although a correlation with cancer phenotype exists, no conclusive evidence has confirmed their oncogenic function.
In a previous paper, we identified a protein bound to mitotic chromosomes in non-tumorigenic canine kidney cells. We named it LFM-1 (Licensing Factor Model-1) by its resemblance to MCM2-7 proteins, a group of molecules with DNA replication licensing activity. We described a LFM-1 58-kDa polypeptide associated with the chromosomal and nuclear fractions in mitosis and G 1 -phase of cell cycle, and also reported its resistance to extraction procedures (3', 5'-diiodosalicylic acid and high ionic strength), a biochemical operational definition for scaffolding/matrix components. In addition, we described the peripheral and axial distribution of the 58-kDa LFM-1 polypeptide on chromatids and the nuclear localization in G 1 nuclei by standard epifluorescence and confocal microscopy. Although analysis of interphase cells revealed the 58-kDa LFM-1-kDa polypeptide included in G 1 nuclei, and a 87-kDa cytoplasmic polypeptide in G 2 -phase cells (Vega-Salas and Salas 1996) , no relationship among these bands was studied. As a preliminary set of data for this study, the chromosomalscaffolding features were explored and confirmed in human epithelial cells. In the present work, we analyze the synthesis, post-translational processing and subcellular localization of LFM-1 chromosomal-scaffold component in human epithelia with contrasting tumorigenicity. Our results support a group of nuclear proteins with transient cellular translocations during the post-translational processing, strong chromosome binding (Gasser et al. 1986; Hennesy et al. 1990 ) and structural/regulatory functions on DNA metabolism (Hernandez-Verdun and Gautier 1994) during cell proliferation events (Stillman et al. 1988; Dohrman et al. 1992; Blow 1993; Coverley et al. 1993; Brazas and Stillman 1993; Madine et al. 1995) . In addition, our findings show an LFM-1 variant with abnormal mass and binding to chromosomes in the cancer phenotype, but, most importantly, they suggest that the reported structural and functional changes in chromosomalscaffold components may be involved in deregulated cell-cycle events of cancer proliferation.
Materials and methods

Cell culture and synchrony
Human breast MCF-10A non-tumorigenic epithelial cells (ATCC CRL) (Soule et al. 1990 ) were grown in D-MEM/F-12, 10% (v/v) horse serum (Gibco, Grand Island, NY), 100 ng/ml cholera toxin, 5 ng/ml epidermal growth factor, and 20 µg/ml hydrocortisone (Gibco, BRL, Gaithersburg, MD). Human breast MCF-7 carcinoma cells (Soule et al. 1973) were kindly provided by I. Luthy (IBYME, Conicet). In both cases, the culture media were supplemented with 1 mM non-essential amino acids, 1 mM sodium pyruvate, 10 µg/ml insulin (Gibco), 100 IU penicillin, and 100 µg/ml streptomycin (Sigma Chemical Co., St. Louis, MO) and kept in 95% air-5% CO 2 , 37°C, in DMEM/F-12, 10% (v/v) fetal bovine serum (Gibco). The cultures were harvested weekly by dissociation in 0.25% trypsin/2 mM ethylenediaminetetraacetic acid (EDTA). The cells were plated at subconfluency (2-6×10 4 cells/cm 2 ) and kept under standard culture conditions 24 h before the experiments.
The span of the cell-cycle phases for each cell line was determined in preliminary experiments by flow cytometry of synchronized cultures. Cells in G 1 -phase were obtained by incubation in starvation media (DMEM no-isoleucine, 10% dialyzed horse or fetal calf serum, and 2 mM L-glutamine) for ~36-48 h. Cultures in S-phase were achieved by cell-cycle arrest in G 1 /S-phase with 2.5 mM hydroxyurea/aphidicolin as described by Nishimoto et al. (1981) and release in normal media. Alternatively, we used 400 µM mimosine in DMEM complete media supplemented with 10% heat inactivated serum for ~12 h (Dijkwel et al. 1991 ) to obtain cells in S-phase. To synchronize cells in G 2 -phase, the cultures were first arrested in G 1 /S and then released from treatment for different times as per the span of cell-cycle phases determined for each cell line. Thus, MCF-10A were released for 3 h (S) and 8 h (G 2 ); or for 2 h (S) and 5 h (G 2 ) in the case of MCF-7 cells. Synchronization in metaphase was achieved by incubation with 0.06 µg/ml nocodazole (Sigma) for ~17-24 h (Vega-Salas and Salas 1996). Before synchronization experiments, MCF10A and MCF-7 (~4×10 4 cells/cm 2 ) were grown on either glass coverslips or plastic roller bottles for 24 or 72 h. To improve the sample homogeneity of collected mitotic cells due to the different attachment of each cell line by nocodazol treatment, we included an additional procedural step of vigorous shake-off of MCF-10A cells, and gentle collection of mitotic MCF-7 cells before the experiments. The success of cell synchrony was determined by a fluorescence-activated cell sorter (FACS) as described below, and by a number of mitotic images observed under the microscope.
FACS analysis
MCF-10A and MCF-7 cells were synchronized as described above, treated with RNase A, stained with propidium iodide, and sorted using a Beckton-Dickinson Facster Plus cell cytometer. To estimate the success of the synchronization, the cellular DNA content was quantified in parallel samples by flow cytometry. The efficiency of synchronization of MCF-10A cells was: G 1 -phase, 84-87%; S/G 2 -phase, 77-82%; mitosis, 72-76%. MCF-7 cells showed: 68-73% (G 1 -phase); 61-65% (S/G 2 -phases), and 65-69% (M-phase). The average of cell synchrony during a complete cell cycle was 72-87% and 61-73% for each phenotype, respectively.
Metabolic labeling
Subconfluent cells were synchronized in different phases of the cell cycle as described previously (Vega-Salas and Salas 1996) . Pulse-chase metabolic labeling was performed with ~1.5 mCi [ 35 S]methionine-[ 35 S]cysteine/ml for ~30 min at 37°C, 95% air, 5% CO 2 on a rocker, after rinsing in DMEM methionine/cysteine free media for 15 min at the start of each cell-cycle phase. Two samples were taken per phase, and immunoprecipitated using LFM-1 MAb and normal mouse IgGs (negative control), electrophoresed in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), dried for ~3 h at 68°C, and exposed for 17 h (PhosphorImager, Molecular Dynamics, Sunnyvale, CA). Additional time-course experiments were performed by incubation of synchronized cultures in G 2 -phase with ~3.5 mCi [ 35 S]methionine-[ 35 S]cysteine/ml for ~2 h. Two points were then taken per cell-cycle phase, immunoprecipitated with LFM-1 MAb, and processed as described above.
Hybridoma production LFM-1 hybridoma was prepared as described previously (VegaSalas and Salas 1996) by fusion of BALB-c mice splenocytes and NS-1 myeloma cells. Briefly, the cell pellets -mostly nuclearfrom MDCK (Madin Darby canine kidney) homogenates were fixed in 3% formaldehyde (from paraformaldehyde, PFA) for 30 min at room temperature. They were then washed twice in Hank's saline buffer solution, and injected intraperitoneally in mice. The screenings were performed by solid-phase radioimmunoassay on monolayers and immunofluorescence on M-phase synchronized cell populations. The reactive immunoglobulins were typed as IgG 1 .
Cell fractionation: nuclear, chromosomal and cytoplasmic fractions Nuclear and cytoplasmic fractions were obtained from nonsynchronized and synchronized cells from both cell lines as described previously (Mirkovich et al. 1984; Vega-Salas and Salas 1996) .The metaphase chromosome fraction was purified from nocodazole-treated cultures (Gasser and Laemmli 1987) . Briefly, subconfluent cultures were then grown in 75-cm 2 plastic flasks (1.3×10 7 cells) or 850-cm 2 roller bottles (1.5-2×10 8 cells). Before the experiments, the cells were rinsed twice and scraped in ice-cold phosphate saline buffer supplemented with an antiprotease inhibitor cocktail [1 mM phenylmethylsulfonyl fluoride (PMSF), 2 µg/ml aprotinin, 10 µg E-64, and 1 µM pepstatin] (Calbiochem, La Jolla, CA), centrifuged and resuspended twice in isolation buffer (3.75 mM TRIS-HCl, 0.5 mM spermine, 0.125 mM spermidine, 20 mM KCl, 1% (v/v) thiodiglycol, and 0.5 mM EDTA/KOH, 0.2 mM PMSF, 5 µg/ml aprotinin, pH 7.4) (Gasser and Laemmli 1987; Vega-Salas and Salas 1996) and isolation buffer supplemented with 0.1% digitonin at 4°C for 3 min (by 15 s alternated sonication). The nuclei were finally pelleted at 1,100 g for 15 min. The resulting supernatants were ultracentrifuged (Beckman L8-70 M) at 100,000 g at 4°C for 1 h, yielding a cytoplasmic (membrane) pellet. Finally, both (nuclear and cytoplasmic) pellets were resuspended in SDS sample buffer, 0.1% β-mercaptoethanol, heated at 95°C for 3 min, and analyzed by SDS electrophoresis in 8-10% polyacrylamide gels as described previously (Vega-Salas and Salas 1996) .
To purify mitotic chromosomes and prophase nuclei, we synchronized cultures in M-phase, harvested them by vigorous shakeoff, centrifuged at 200 g for 10 min, and washed twice in solution I: hypotonic buffer (7.5 mM TRIS Cl, 40 mM KCl, 1 mM EDTA/KOH, 0.1 mM spermine, 0.5 mM spermidine, pH 7.4), 1% (v/v) thiodiglycol, and antiprotease inhibitor cocktail (mentioned above) containing 5 µg/ml aprotinin. The cells were then centrifuged at 800 g for 5 min, resuspended in ice-cold solution II ×2 hypotonic buffer [1% (v/v) thiodiglycol, 5 µg/ml aprotinin, 1 mM PMSF, 0.1% digitonin], disrupted with ten strokes of a Dounce homogenizer and let stand on ice for 10 min. The homogenates were placed over a 5-70% glycerol gradient in solution III, 1:2 hypotonic buffer in 2d H 2 O (1% thiodiglycol, 0.1% digitonin, antiprotease cocktail), and centrifuged in a swing-out rotor for 5 min at 200 g, followed by 15 min at 700 g. The chromosomes recovered in the lower part of the gradient, were centrifuged again into 5 ml cushion of 70% glycerol at 3,500 g for 15 min and stored in this cushion at -20°C before immunofluorescence or PAGE processing. In both cases, the fractions were monitored by phase microscopy and immunoblot using polyvalent antibodies against tubulin and cytokeratins for control of cytoplasmic contamination. No further purification procedures were required even in the case of MCF-10A cells, which showed a higher resistance to fractionation than MCF-7 cells.
Indirect immunofluorescence
The standard method for immunofluorescence labeling of whole tissue culture cells has been described previously (Vega-Salas et al. 1987; Vega-Salas and Salas 1996) . Synchronized cells as described above were fixed, permeabilized in 0.2% Triton X-100/0.15% saponin or 70/30% methanol/acetone at -20°C, and processed with LFM-1 MAb supernatant (1:3 in PBS) and 20 µg/ml affinity purified goat anti-mouse IgGs coupled to fluorescein (with minimal cross-reactivity to human proteins, Jackson Labs., West Grove, PA). Negative controls were incubated with 10 µg/ml mouse preimmune IgGs. Isolated nuclei or chromosomes were processed by standard immunofluorescence procedures but after incubations the samples were washed by ~3 min spinning/ resuspension cycles. During the procedures, nuclei were kept in PBS supplemented with 1 mM MgCl 2 and 0.1 mM CaCl 2 while chromosomes were maintained in hypotonic buffer (15 mM TRIS-HCl, 80 mM KCl, 2 mM EDTA/KOH, 0.2 mM spermine, 0.1 mM spermidine, pH 7.4, 1% thiodiglycol, 5 µg/ml aprotinin, and 1 mM PMSF) (Gasser and Laemmli 1987) to avoid aggregation.
When colocalization with chromatin was aimed at, the samples were pretreated with 1 mg/ml RNase-A (Sigma) for 15 min at room temperature immediately after the second antibody and prior to the incubation with 1 mg/ml propidium iodide. Finally, cells, nuclei or isolated chromosomes were thoroughly washed before mounting in a mix of 1:1 polyvinyl alcohol (20% polyvinyl alcohol, 15% glycerol, 1% n-propyl gallate in PBS) and Slowfade (Molecular Probes, Eugene, OR) as described previously (VegaSalas and Salas 1996) . The images were visualized under a Leitz DM RB epifluorescence microscope (Leica, Wetzar, Germany) using T-Max 400 ASA or Ektachrome 160T film (Kodak). To control cytoskeletal contaminations, we incubated the cells with rabbit polyvalent antibodies against tubulin, actin and cytokeratins, and affinity purified goat against rabbit IgGs, fluorescein isothiocyanate (FITC) or peroxidase-labeled second antibodies.
Confocal microscopy
Isolated nuclei from MCF-10A and MCF-7 cells were processed by immunofluorescence as described above, and analyzed by laser confocal microscopy (Molecular Dynamics, Sunnyvale, CA). Usually, 40-62 confocal sections were taken (0.1 µm thick) throughout two detection channels and three-dimensionally reconstructed using image analysis software (Molecular Dynamics).
SDS-PAGE and immunoblot
Human biopsies from normal tissues and carcinomas were obtained from the Tissue Procurement facility of the Sylvester Comprehensive Cancer Center, University of Miami. The samples ranging 130 to 250 mg were kept in liquid nitrogen until homogenization in 150-300 µl ×4 sample buffer, 6 M urea for 4-6 min on ice. Normalization of protein content was done by the Bradford test prior to plating the gels. Aliquots of homogenates of human biopsies or fractions of tissue culture cells (20-120 µl/lane) were electrophoresed by standard 8-10% SDS PAGE (Laemmli 1970) , electroblotted onto nitrocellulose (Towbin et al. 1979) , and developed by a peroxidase-detection chemiluminescence system (ECL, Amersham, Bucks, UK). The immunoreagents were LFM-1 MAb (1:3 in PBS), affinity purified goat anti-mouse IgGs-biotin conjugated (1:2000, Sigma), and Extravidin-peroxidase (1:2500, Sigma) in 0.1% Tween-20/PBS, 1 mM MgCl 2 , 0.1 mM CaCl 2 . The tissue biopsies reported in this paper were as follows (Fig. 4 , from left to right): normal breast and ductal breast carcinoma (same patient); breast adenocarcinoma, normal colon; colon adenocarcinoma; normal breast; poorly differentiated breast adenocarcinoma; normal skin; skin melanoma; normal kidney; kidney cell carcinoma; and kidney Wilms' carcinoma.
To determine the phosphoepitopes in LFM-1 polypeptides, MCF-10A and MCF-7 cells were grown at subconfluency for 24 h, harvested on ice-cold PBS supplemented with protease inhibitors, immunoprecipitated using LFM-1 MAb, and processed by SDS-PAGE and Western blot. The nitrocellulose sheets were developed by standard chemiluminescence procedures using antiserine, threonine, and tyrosine MAbs (Sigma, cat. 3430, 3555 and 3300) and goat anti-mouse, peroxidase-labeled IgGs.
Alkaline phosphatase Confluent non-synchronized 1.5-2×10 7 MCF-10A and MCF-7 cells were harvested by scraping in the presence of antiprotease inhibitor cocktail, homogenized and fractionated in nuclear and cytoplasmic pellets as described above. Each fraction was resuspended in 100 µl final volume (200 mM CO 3 Na 2 /CO 3 HNa buffer, pH 9.8), supplemented with 0.5 mM MgCl 2 , and separated into two aliquots. One of these samples was incubated with 80 DEA units of type VII-NL bovine alkaline phosphatase (orthophosphoricmonoester phosphohydrolase) from intestine mucosa (Sigma, cat. no. 3131) in 50 mM TRIS HCl, 1 mM MgCl 2 , 0.1 mM ZnCl 2 , 1 mM spermidine, pH 8.9, for 40 min at 37°C. The reaction was then stopped in 6 mM TRIS, 0.8 mM EDTA, 150 mM NaCl, pH 7.5, the enzyme was removed by two cycles of centrifugation/ resuspension, and the final pellets were processed by PAGE and immunoblot.
Results
LFM-1 protein abnormally binds to mitotic chromosomes in tumor cells
LFM-1 subcellular distribution and association with chromosomes in human epithelia were analyzed in human subconfluent MCF-10A and MCF-7 cells during the cell cycle by standard epifluorescence and confocal microscopy. The brightest LFM-1 signal was observed on mitotic chromosomes (Fig. 1a, d and f, i) . A continuous intense LFM-1 mark was observed in the periphery of condensing chromosomes in prophase nuclei (Fig. 1a , white arrowheads) and surrounding metaphase plaques (Fig. 1d , white arrowheads) in MCF-10A non-tumorigenic cells consistent with our previous observations in canine microscopy (b, c, g, h) . b, g Single medial confocal optical sections (0.1 µm thick) and c, h the corresponding 3D reconstitution (by look-through projections) of the stack of sections. Note a brighter LFM-1 signal decorating condensing MCF-10A (a-c) but not MCF-7 (f-h) chromosomes on both epifluorescence (a, f) and confocal images (b, c and g, h) (arrowheads). However, although nuclear envelope/chromosome contact areas were positive in both cell phenotypes, a decreased LFM-1 signal was observed in carcinoma cells. Isolated metaphase chromosomes from non-tumorigenic cells (e) displayed uniform LFM-1/fluorescein signal (green) surrounding the chromatids (red) while chromosomes from MCF-7 cells (j) displayed a heterogeneous fluorescence pattern often with no LFM-1 labeling (j, big white arrowheads). Scale bars 5 µm (a, d, f, i), 2.5 µm (e-j), 3 µm (b, c, g, h) kidney non-tumorigenic cells (Vega-Salas and Salas 1996) . However, in contrast, a decreased labeling of LFM-1 was suspected in nuclei of MCF-7 carcinoma cells (Fig. 1f, i) .
To further investigate the extent of LFM-1 association with chromosomes in the cancer phenotype, purified chromosome fractions of MCF-10A and MCF-7 cultures in M-phase were comparatively analyzed by immunofluorescence and confocal microscopy. These preparations contained some prophase nuclei that were included in this study (Fig. 1b, c, g, h) . Approximately 90 prophase nuclei per cell line were examined colocalizing DNA (propidium iodide after RNase treatment, red channel) and LFM-1 epitopes (fluorescein, green channel). Consistent with the images from unfractionated cultures (Fig. 1a, f) , confocal tridimensional images displayed LFM-1 epitopes overlapping the condensing chromosomes in localized nuclear peripheral areas in MCF-10A cells. Despite a grossly conserved nuclear fluorescence pattern of LFM-1 in both cell lines, a faint signal in MCF-7 tumor cells was observed (Fig. 1c, h, arrows) , which was further confirmed by the analysis of the confocal sections (Fig. 1b, g ). Since images in b and g are 0.1-µm confocal sections, the general reduction of LFM-1 epitopes was evident in both the periphery and axis of the chromatids in cancer cells (Fig. 1b) . Consistent with these findings, isolated mitotic chromosomes from MCF-7 carcinoma cells showed a heterogeneous LFM-1 labeling. The fluorescence ranged from bright/undetectable signal (Fig. 1j, big white arrowheads) , including a less common configuration of patchy positive areas clearly contrasting with the homogeneous subcellular distribution observed in non-tumorigenic cells (Fig. 1i) . As a conclusion of these studies, LFM-1 protein displays a notorious heterogeneous and decreased chromosome binding to chromosomes in cancer cells (Fig. 1c, h , yellow signal, white arrowheads).
Carcinoma cells display a molecular LFM-1 variant associated with mitotic chromosomes
To identify the LFM-1 molecular species bound to mitotic chromosomes, unsynchronized cultures from both cell lines were fractionated in nuclear and cytoplasmic pellets as described previously (Vega-Salas and Salas 1996). The nuclei -referred to hereafter as nuclear fractionand the postnuclear supernatant (membrane pellet) (Mirkovich et al. 1984; Gasser and Laemmli 1987) were processed by SDS-PAGE (Fig. 2A) . The purified nuclear fraction of MCF-10A cells showed a major 58-kDa and secondary 65-and 87-kDa LFM-1 bands (Fig. 2N,  asterisk) . In contrast, the equivalent Western blot of MCF-7 nuclei displayed a 60-kDa polypeptide (arrowhead) and similar 65-and 87-kDa minor bands. Because LFM-1 signal detected in the nuclear fraction comprised all LFM-1 polypeptides associated with nuclei and chromosomes during a complete cell cycle, we decided to further discriminate the specific LFM-1 polypeptide(s) bound to chromosomes during M-phase. Accordingly, the pattern of bands from the purified chromosome fraction in M-phase was compared with the one in unsynchronized cultures ( Fig. 2A, N , B, Chr). As a result, mitotic chromosomes of MCF-10A non-tumorigenic cells displayed a defined unique 58-kDa LFM-1 major band (Fig. 2Chr, asterisk) . In contrast, MCF-7 carcinoma cells showed a major 60-kDa LFM-1 polypeptide (Fig. 2Chr, arrowhead) and modest minor 65-and 87-kDa polypeptides. These observations were extended and confirmed in normal and cancer biopsies from human breast, colon, skin and kidney epithelia. A correlated 58-kDa LFM-1 electrophoretic band was obtained from biopsies of normal epithelia in contrast 197 Fig. 2A , B LFM-1 molecular species associated with the nuclear (N) and cytoplasmic (C) fractions (A) and chromosome fraction (B, Chr) in human non-tumorigenic (MCF-10A) and tumorigenic (MCF-7) cells. Unsynchronized cultures (A) were harvested, fractionated, and the nuclear and cytoplasmic pellet processed by SDS-PAGE and immunoblot. A 58-kDa LFM-1 band is identified in the nuclear fraction of MCF-10A non-tumorigenic cells (*). MCF-7 carcinoma cells instead display a 60-kDa LFM-1 polypeptide (arrowhead). Cells synchronized in M-phase by nocodazol treatment were homogenized and the chromosomes isolated (Chr). The remaining attached cells to the substrate (in interphase) were then scraped and fractionated to obtain the nuclear pellet (N). A major 58-kDa band is the major LFM-1 polypeptide identified in the chromosome (Chr) fraction of MCF-10A non-tumorigenic cells (*), while a 60-kDa band was detected in mitotic chromosomes of MCF-7 carcinoma cells (arrowhead) (arrows 86, 66, and 56 kDa: molecular weight markers) with a 60-kDa polypeptide in carcinomas from several organs. Figure 3 shows the correlation between both LFM-1 forms in tissues and tumor biopsies.
The consistent findings in human tissues point to the 58-kDa band as the major LFM-1 polypeptide in normal epithelia, and the 60-kDa band as its correlated chromosome polypeptide in cancer cells, and also suggest an involvement of the chromosome scaffold/matrix in the cancer phenotype.
A common LFM-1 precursor is synthesized in G 2 in both non-tumorigenic and cancer cells
The identification of a 58-kDa LFM-1 chromosome band in non-tumorigenic cells and a 60-kDa variant in cancer cells compelled us to discriminate between unrelated molecules with similar LFM-1 antibody recognition and differential post-translational processing of a common LFM-1 precursor (phenotype-dependent feature). As a first approach, MCF-10A and MCF-7 cells were synchronized in G 1 -, S-, and G 2 -phases of the cell cycle, metabolically labeled with [ 35 S]methionine/cysteine, immunoprecipitated with LFM-1 MAb and analyzed by autoradiogram. A unique 87-kDa LFM-1 polypeptide was detected in both cell lines in G 2 -phase (Fig. 4A, B , asterisks), which correlated with the highest molecular band detected in cell homogenates of unsynchronized cultures (Figs. 2, 3) . No additional bands were detected even with longer pulse labeling, and/or film exposure through a complete cell cycle, supporting the idea that the 87-kDa polypeptide is the unique LFM-1 precursor. In addition, quantification of the [ 35 S]-labeling of LFM-1 87-kDa bands was performed in both phenotypes using Image-Quant software. The immunoprecipitation controls (Fig. 4C) . Although the efficiency of cell synchronization was higher for MCF-10A cells, the corrected values (integration unit per synchronized cell) showed higher synthesis of LFM-1 precursor in carcinoma cells (see "Efficiency of cell synchronization" in "Materials and methods").
LFM-1 polypeptides are post-translational products of the 87-kDa precursor To study the relationship among LFM-1 polypeptides, synchronized cultures in G 2 were pulse-labeled with [ 35 S]methionine/cysteine for ~2 h and released for different times based on the previously determined cell cycle span of each cell line. Two samples were taken per cell cycle phase, immunoprecipitated with LFM-1 MAb, and processed by SDS-PAGE and autoradiogram (Fig. 5) . We found a rapid post-translational modification of the 87-kDa-to 65-kDa and 58-kDa LFM-1 polypeptides during G 2 -phase. Consequently, the 58-kDa band was the major band detected in mitosis and afterwards in G 1 -and S-phases (Fig. 5A', C, C', E, E', G) . MCF-7 carcinoma cells instead displayed a 60-kDa polypeptide from the onset of M-phase until S-phase, and a similar equivalent general pattern of LFM-1 bands consistently reported in previous experiments ( Fig. 2A, B, arrowheads) .
Altogether, these results show the appearance of a 60-kDa LFM-1 post-translational variant in cancer cells despite the synthesis of a common 87-kDa precursor in G 2 -phase and a similar cell-cycle profile of posttranslational processing in both cell phenotypes.
LFM-1 polypeptides are differentially phosphorylated. Those mostly containing Tyr and Thr are sensitive to dephosphorylation.
To explore the relationship among LFM-1 bands and correlate it with the subcellular localization, we first determined the amino acid phosphoepitopes in LFM-1 polypeptides (Fig. 6A) . Parallel to changes in the apparent molecular weight of LFM-1 polypeptides, variations in its amino-acid phosphorylation were detected in unsynchronized MCF-10A cells by immunoprecipitation and electrophoresis/Western blotting. LFM-1 phosphoepitopes were assayed, reacting the nitrocellulose membranes with antiphosphoserine, phosphothreonine, and phosphotyrosine MAbs, and chemiluminescence. The analysis of epitope phosphorylation of LFM-1 polypeptides did not reveal any ostensible difference in equivalent LFM-1 bands in both cell lines. While the 87-kDa band was phosphorylated in tyrosine, threonine and serine, the in lanes B,B', D,D', F,F' and H,H' . Bars point to standard molecular weights of 86, 66 and 56 kDa. The autoradiogram in MCF-7 cells displayed an equivalent pattern of bands, but a 60-kDa polypeptide was observed instead of the 58-kDa band (not shown) Fig. 6 Determination of tyrosine, threonine, and serine phosphoepitopes in LFM-1 polypeptides (A), and changes in mass of LFM-1 polypeptides by alkaline phosphatase treatment (B). A LFM-1 polypeptides were immunoprecipitated from whole cell extracts of unsynchronized cultures. Negative controls were carried out with normal mouse IgGs. The elutes were electrophoresed and processed by immunoblot using monoclonal antibodies against phosphothreonine, phosphotyrosine and phosphoserine. A, C, E Immunoprecipitation with LFM-1 MAb. B, D, F Immunoprecipitation control. Tyrosine phosphorylation is mostly detected in 87-kDa LFM-1 precursor, while phosphorylation in threonine is present in the 87-kDa LFM-1 precursor and the 58-kDa chromosome-associated band as well. However, serine phosphorylation is mainly observed in the 58-kDa LFM-1 chromosome/nuclear polypeptide. B Confluent unsynchronized MCF-10A (A, B, A', B' ) and MCF-7 (C, D, C', D') cells were harvested, homogenized and fractionated in nuclear and cytoplasmic pellets. One of each sample was incubated with alkaline phosphatase (+), and the final pellets were processed by PAGE and immunoblot. Note the degradation of LFM-1 87-and 65-kDa cytoplasmic polypeptides in both cell phenotypes with a shift in the mass of only the 60-kDa LFM-1 chromosome form in the nuclear fraction. Arrowhead points to 60-kDa band; asterisk indicates 58-kDa LFM-1 polypeptide minor intermediate 65-kDa LFM-1 polypeptide displayed phosphorylation in tyrosine and threonine, and the major 58/60-kDa chromosomal forms showed mostly marked serine phosphoepitopes (Fig. 6A) .
To further determine the extent of involvement of dephosphorylation processes in the post-translational modifications of LFM-1 polypeptides, we explored the sensitivity of LFM-1 polypeptides to alkaline phosphatase treatment. Accordingly, MCF-10A and MCF-7 cells were homogenized and separated into nuclear and cytoplasmic fractions as described in "Materials and methods." One aliquot of each sample was treated with alkaline phosphatase (Fig. 6B, +) and a parallel one kept as control (Fig. 6B, -) . It is important to mention that the common treatment of all samples with a common batch of alkaline phosphatase provided an internal reliable control for the purity of the enzyme potentially contaminated with antiproteases. No major changes in mass of LFM-1 nuclear bands were detected in either cell line by alkaline phosphatase treatment (Fig. 6B, A , B, C, D) despite an increased degradation of the 60-kDa polypeptide in the nuclear fraction of MCF-7 cells, resulting in small polypeptides in front of the gel (Fig. 6B, D) . The treatment of the cytoplasmic pellets by alkaline phosphatase, however, dramatically changed the regular pattern of LFM-1 bands in both cells. The 87-kDa LFM-1 precursor was significantly degraded by the enzymatic treatment to an evident intermediate 65-kDa LFM-1 band in MCF-10A cells (Fig. 6B, A', B' ). However, although a dephosphorylation process was evident in the cytoplasmic fraction of MCF-7 carcinoma cells, the 87-kDa LFM-1 precursor significantly degraded mostly to unspecific polypeptides in the front of the gel, with no intermediate products (Fig. 6C', D' ).
These results show parallel changes in the common post-translational phosphorylation processing of the 87-kDa LFM-1 precursor in both cell phenotypes. However, they suggest a dissimilar sensitivity of the 87-kDa precursor and intermediate products to dephosphorylation in both cell phenotypes.
Discussion
LFM-1 in human tissues
In this work, we identify and study LFM-1 protein in human cell lines and tissues, analyze its synthesis and post-translational processing, and report on differences in the post-translational chromosome form in cancer cells. Despite lineage and species differences, LFM-1 apparent molecular weight and subcellular distribution in human normal epithelia (breast, kidney, colon, and skin) correlate with that previously reported in MDCK nontumorigenic dog kidney epithelium (Vega-Salas and Salas 1996) , supporting the idea that LFM-1 is a well conserved protein. Most importantly, this study reports a 60-kDa LFM-1 form which displays consistent changes in its relative molecular mass and binding to chromosomes in a variety of human cancer cells. Altogether, these results and the transient LFM-1 binding to chromosomes during progression of the cell cycle suggest that the 60-kDa LFM-1 variant may be related to the cancer phenotype and play a role in malignant cell proliferation.
Relationship between LFM-1 bands: synthesis and post-translational processing; shift in the mass of the LFM-1 chromosome form in cancer cells
The first hypothesis one can postulate to explain the multiband pattern of LFM-1 polypeptides is the monoclonal recognition of a common epitope in unrelated polypeptides. However, our results strongly suggest it is unlikely. Cell metabolic labeling showed only one LFM-1 precursor during the entire cell-cycle. If other unspecific polypeptides had been recognized by the LFM-1 antibody, it should have resulted in the appearance of additional bands, which was not the case. In addition, experiments of time-course cell labeling displayed an LFM-1 pattern of bands correlating with the one reported in unsynchronized cultures. These results suggest that the 60-and 58-kDa LFM-1 chromosome polypeptides originate from a common 87-kDa LFM-1 precursor by means of cytoplasmic post-translational phosphorylation processing. Most importantly, they show molecular and functional changes in the 60-kDa post-translational polypeptide in cancer cells. In this regard, a correlation has been reported between modest changes in the molecular weight of proteins and their DNA binding ability after post-translational modifications (Luscher and Eisenman 1992) . Often these modifications involve phosphorylation processes that regulate complementary proteolytic cleavages of the polypeptide chain (Reddy et al. 1991) . Currently, we cannot rule out a change in the primary structure of LFM-1 precursor, nor in the post-translational machinery of cancer cells for the abnormal mass and binding to chromosomes in the cancer phenotype.
It has been reported that dephosphorylation processing in tyrosine and threonine epitopes with parallel serine phosphorylation exert regulatory key functions on subcellular distribution, mass, and functions of a number of cytoplasmic proteins (Reddy et al. 1991; Tyers et al. 1992; Ng et al. 1992; Swarup and Radha 1992; Johnson and Foley 1993; Elvira et al. 1993) . The simultaneous molecular and functional changes on LFM-1 polypeptides with parallel cell-cycle-dependent cellular translocations during post-translational phosphorylation processing support these data.
Similarities of LFM-1 with known proteins; potential functions Interestingly, the results in this paper partially resemble a few proteins in the literature which are cell proliferation related. One of them, SWI5, shows a comparable cellcycle temporal translocation: it enters into the nucleus in M-phase (the mitosis in yeast is closed), binds to chromosomes in anaphase, remains nuclear during G 1 -phase (exerting regulatory functions at the onset of start) and is degraded afterwards (Blow 1993; Coverley et al. 1993) . SATB1 (specific A-T binding) is a recently reported nuclear-matrix protein (Dickinson et al. 1992; Yanagisawa et al. 1996; de Belle et al. 1998) . Despite some common features with LFM-1 such as binding to MAR/SAR areas of DNA, and a similar apparent molecular weight, there is no significant sequence homology between these proteins.
As a chromosomal-scaffold component, LFM-1 protein may have a function in the higher order chromatin folding, and also a role in gene expression. To date, our findings suggest that LFM-1 might exert function(s) on DNA metabolism during progression of the cell cycle somewhat comparable to MCM2-7 DNA replication licensing factors (Blow 1993 (Blow , 2001 Coverley et al. 1993) . However, to date there is no evidence to support a relationship with this group of proteins.
In this paper, we report a correlation between 60-kDa LFM-1 polypeptide and cancer phenotype. Cancer cells in contrast with non-tumorigenic or normal tissues exhibited only one single (mostly unique) 60-kDa LFM-1 band defectively associated with chromosomes. Consistently, LFM-1 subcellular distribution in nuclear peripheral areas of potential telomere segregation, and decreased chromosome labeling observed in cancer cells, suggest a potential dysfunction in cell-cycle-related events. It is suggestive of the telomeric localization of LFM-1 protein and the data in the literature reporting regulatory functions of telomeres and telomerase activity on cell proliferation (Price 1992; Harley 1992; Jacob et al. 2001) . In this regard, other chromosomal-scaffolding components such as RAP-1, a 116-kDa abundant protein with a role in the control of DNA proliferation (Klein et al. 1992) , also termed TUF (Vignais and Sentenac 1989) , and GRF-1 (Shuey and Parker 1986) , have been reported to be mainly bound to telomeric areas. Also, CAP, a chromosomal auxiliary protein with similar chromosome binding to LFM-1, has been reported to play a role in DNA-bending at specific sites during gene regulation in yeast (LiuJohnson et al. 1986 ), activating genes essential for the initiation of DNA replication (Koepsel and Khan 1986) , and preventing telomere-telomere joining and degradation (Bourgain and Katinka 1991) .
During the last few years, changes in the nuclear matrix have been reported in cancer cells. Malignancyrelated two-dimensional gel spots have been described in a variety of human cancers (Keesee et al. 1994; Getzember and Coffey 1991; Kanuja et al. 1993) . Despite these findings not yet having been assessed for specific cancer-related function(s), the study of these polypeptides may open a new avenue in the understanding of cancer biology and its potential treatment as well. The consistent results reported in this work on LFM-1 in a broad range of human malignancies suggest that 60-kDa LFM-1 polypeptide can be involved in malignant cell proliferation events. It is still hard to ascertain whether LFM-1 differences detected in tumor cells play a role in the malignant phenotype or are just a consequence of defective metabolic pathways or regulatory processes in tumor cells. However, the correlation between LFM-1 60-kDa polypeptide and cancer phenotype leads to the possibility of a dysfunction of chromosomematrix components in the deregulated cancer proliferation. Although the 58-kDa/60-kDa polypeptides could be more relevant to tumor biology (in the case of a potential relationship with similar oncogenes and tumor suppressor genes expressed in tumors), the reported changes in the LFM-1 post-translational polypeptide in cancer cells may shed new insights by suggesting unsuspected structural/ regulatory function(s) in the cancer phenotype.
